Bispecific antibody · Immune activation, directed at undisclosed antigen 1 on tumor-infiltrating Tregs and undisclosed antigen 2 on tumor-infiltrating Tregs · developed by Agenus
AGEN1223 is a bispecific antibody that binds two undisclosed antigens co-expressed on tumor-infiltrating regulatory T cells. It selectively depletes immunosuppressive Tregs in the tumor microenvironment while sparing peripheral Tregs and effector T cells, and may co-stimulate antigen-specific effector T cells. It is studied in advanced solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04156100 | Phase 1 | Advanced Solid Tumor | Terminated | AGEN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid Tumor
Updated Oct 3, 2026. Something wrong or missing? Report it on the AGEN page.
See AGEN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
AGEN catalysts and pipeline →